Research graph
References from Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Pulmonary sarcomatoid carcinoma: an analysis of the National cancer data base
10.1016/j.cllc.2016.11.016 · 2017 · External reference
Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases
10.1186/1477-7819-11-252 · 2013 · External reference
The 2021 WHO classification of lung tumors: impact of advances since 2015
10.1016/j.jtho.2021.11.003 · 2022 · External reference
Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis
10.1016/j.athoracsur.2016.08.114 · 2017 · External reference
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma
10.1097/01.jto.0000437008.00554.90 · 2013 · External reference
Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung
10.1016/j.cllc.2016.03.001 · 2016 · External reference
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024
10.1007/s10147-021-02113-5 · 2022 · External reference
Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling
10.1016/j.jtho.2017.03.005 · 2017 · External reference
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma
10.1016/j.jtho.2020.01.014 · 2020 · External reference
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
10.1016/j.ejca.2020.03.029 · 2020 · External reference
Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma: a pooled analysis
10.1016/j.cllc.2020.02.022 · 2020 · External reference
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
10.1097/jto.0b013e318292be18 · 2013 · External reference
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
10.1016/j.lungcan.2016.05.013 · 2016 · External reference
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy
10.1007/s00432-019-03023-w · 2019 · External reference
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas
10.1016/j.ejca.2015.08.013 · 2015 · External reference
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
10.1002/jso.25041 · 2018 · External reference
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas
10.1038/s41598-019-40016-8 · 2019 · External reference
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
10.1016/j.esmoop.2025.105343 · 2025 · External reference
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma
10.1038/s41379-018-0053-3 · 2018 · External reference
Differential expression of immune checkpoints (PD-L1, HHLA2, B7x and B7H3) and their association with driver mutations in pulmonary sarcomatoid carcinoma (PSC)
2018 · External reference
Heterogeneous expression of PD-L1, B7x, B7-H3, and HHLA2 in pulmonary sarcomatoid carcinoma and the related regulatory signaling pathways
10.3390/cancers15133372 · 2023 · External reference
Evaluation of the effectiveness and safety profile of first-line immune checkpoint inhibitors combined with chemotherapy in pulmonary sarcomatoid carcinoma
2025 · External reference
P1.01-64 predictive value of K-Ras subset mutations and PD-L1 in pulmonary sarcomatoid carcinoma (PSC)
10.1016/j.jtho.2019.08.779 · 2019 · External reference
Effectiveness and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in pulmonary sarcomatoid carcinoma
2024 · External reference
Distinct clinicogenomic features and immunotherapy associations in pulmonary sarcomatoid carcinoma: a multicenter retrospective study
10.1016/j.jtho.2025.07.121 · 2025 · External reference
Prognostic significance of tumor immunity in surgically resected pulmonary pleomorphic carcinoma
10.21873/anticanres.13948 · 2020 · External reference
A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study
10.1093/jjco/hyab202 · 2022 · External reference
Genomic landscape of pulmonary sarcomatoid carcinoma
10.4143/crt.2023.764 · 2024 · External reference
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series
10.1016/j.pathol.2025.07.009 · 2026 · External reference
Immunophenotyping of pulmonary sarcomatoid carcinoma
10.3389/fimmu.2022.976739 · 2022 · External reference
Immunotherapy-extended survival in patients with recurrent pulmonary pleomorphic carcinoma following surgery
10.1016/j.ejso.2024.109565 · 2025 · External reference
A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis
10.2169/internalmedicine.1462-18 · 2019 · External reference
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas
10.1111/his.13466 · 2018 · External reference
High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma
10.1007/s00595-021-02439-7 · 2022 · External reference
Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma
10.1007/s12032-017-1000-8 · 2017 · External reference
Ringed fluorodeoxyglucose uptake predicted poor prognosis after resection of pulmonary pleomorphic carcinoma
10.1186/s13019-022-01799-6 · 2022 · External reference
PD-L1 expression in surgically resected lung pleomorphic carcinoma - one-centre study of 107 patients
10.1016/j.jtho.2023.09.407 · 2023 · External reference
Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
10.3904/kjim.2017.245 · 2018 · External reference
Integrated clinical, molecular and immunological characterization of pulmonary sarcomatoid carcinomas reveals an immune escape mechanism that may influence therapeutic strategies
10.3390/ijms241310558 · 2023 · External reference
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1
10.1016/j.prp.2020.153238 · 2020 · External reference
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: a multicenter retrospective study
10.4149/neo_2022_220617n644 · 2022 · External reference
18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings
10.1007/s12149-019-01374-5 · 2019 · External reference
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
10.1016/j.lungcan.2024.108068 · 2025 · External reference
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis
10.1371/journal.pone.0180346 · 2017 · External reference
Genomic variations and immune-related features of TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese pulmonary sarcomatoid carcinoma
10.2147/ijgm.s357659 · 2022 · External reference
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
10.1177/17588359221136759 · 2022 · External reference
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
10.1016/j.lungcan.2021.01.006 · 2021 · External reference
Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data
10.1097/xeb.0000000000000054 · 2015 · External reference
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
10.1111/1759-7714.13684 · 2020 · External reference
Clinical characteristics and PD-L1 expression of pulmonary sarcomatoid carcinoma
2017 · External reference
Immune checkpoint inhibitors plus chemotherapy as first-line treatment in patients with advanced pulmonary sarcomatoid carcinoma
10.1016/j.jtho.2024.09.733 · 2024 · External reference
Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
10.1177/17588359221133889 · 2022 · External reference
Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma
10.1111/ajco.13460 · 2021 · External reference
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter Express study
10.1016/j.lungcan.2019.06.012 · 2019 · External reference
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
10.1038/s41598-024-80301-9 · 2025 · External reference
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
10.1177/1758835920950207 · 2020 · External reference
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015 · External reference
Signatures of mutational processes in human cancer
10.1038/nature12477 · 2013 · External reference
PD-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · 2014 · External reference
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
10.1158/1078-0432.ccr-16-2554 · 2017 · External reference
Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer
10.1097/jto.0000000000000687 · 2015 · External reference
Characteristics and predictive value of PD-L1 status in real-world non-small cell lung cancer patients
10.1097/cji.0000000000000226 · 2018 · External reference
The repertoire of mutational signatures in human cancer
10.1038/s41586-020-1943-3 · 2020 · External reference
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
10.1038/ncomms6241 · 2014 · External reference
Immunosuppressive traits of the hybrid epithelial/mesenchymal phenotype
10.3389/fimmu.2021.797261 · 2021 · External reference
PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project
10.1016/j.jtho.2016.11.2228 · 2017 · External reference
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
10.1002/jso.25041 · ExternalCitation · doi-reference
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy
10.1007/s00432-019-03023-w · ExternalCitation · doi-reference
High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma
10.1007/s00595-021-02439-7 · ExternalCitation · doi-reference
Phase II study of carboplatin-paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024
10.1007/s10147-021-02113-5 · ExternalCitation · doi-reference
Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma
10.1007/s12032-017-1000-8 · ExternalCitation · doi-reference
18F-FDG PET/CT imaging in pulmonary sarcomatoid carcinoma and correlation with clinical and genetic findings
10.1007/s12149-019-01374-5 · ExternalCitation · doi-reference
Pathologic findings and long-term results after surgical treatment for pulmonary sarcomatoid tumors: a multicenter analysis
10.1016/j.athoracsur.2016.08.114 · ExternalCitation · doi-reference
Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung
10.1016/j.cllc.2016.03.001 · ExternalCitation · doi-reference
Pulmonary sarcomatoid carcinoma: an analysis of the National cancer data base
10.1016/j.cllc.2016.11.016 · ExternalCitation · doi-reference
Relationship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmonary sarcomatoid carcinoma: a pooled analysis
10.1016/j.cllc.2020.02.022 · ExternalCitation · doi-reference
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas
10.1016/j.ejca.2015.08.013 · ExternalCitation · doi-reference
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
10.1016/j.ejca.2020.03.029 · ExternalCitation · doi-reference
Immunotherapy-extended survival in patients with recurrent pulmonary pleomorphic carcinoma following surgery
10.1016/j.ejso.2024.109565 · ExternalCitation · doi-reference
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis
10.1016/j.esmoop.2025.105343 · ExternalCitation · doi-reference
PD-L1 immunohistochemistry assays for lung cancer: results from Phase 1 of the blueprint PD-L1 IHC assay comparison project
10.1016/j.jtho.2016.11.2228 · ExternalCitation · doi-reference
Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling
10.1016/j.jtho.2017.03.005 · ExternalCitation · doi-reference
P1.01-64 predictive value of K-Ras subset mutations and PD-L1 in pulmonary sarcomatoid carcinoma (PSC)
10.1016/j.jtho.2019.08.779 · ExternalCitation · doi-reference
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma
10.1016/j.jtho.2020.01.014 · ExternalCitation · doi-reference
The 2021 WHO classification of lung tumors: impact of advances since 2015
10.1016/j.jtho.2021.11.003 · ExternalCitation · doi-reference
PD-L1 expression in surgically resected lung pleomorphic carcinoma - one-centre study of 107 patients
10.1016/j.jtho.2023.09.407 · ExternalCitation · doi-reference
Immune checkpoint inhibitors plus chemotherapy as first-line treatment in patients with advanced pulmonary sarcomatoid carcinoma
10.1016/j.jtho.2024.09.733 · ExternalCitation · doi-reference
Distinct clinicogenomic features and immunotherapy associations in pulmonary sarcomatoid carcinoma: a multicenter retrospective study
10.1016/j.jtho.2025.07.121 · ExternalCitation · doi-reference
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
10.1016/j.lungcan.2016.05.013 · ExternalCitation · doi-reference
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter Express study
10.1016/j.lungcan.2019.06.012 · ExternalCitation · doi-reference
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
10.1016/j.lungcan.2021.01.006 · ExternalCitation · doi-reference
Efficacy of immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma and predictive potential of mutated TP53
10.1016/j.lungcan.2024.108068 · ExternalCitation · doi-reference
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series
10.1016/j.pathol.2025.07.009 · ExternalCitation · doi-reference
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1
10.1016/j.prp.2020.153238 · ExternalCitation · doi-reference
Signatures of mutational processes in human cancer
10.1038/nature12477 · ExternalCitation · doi-reference
PD-1 blockade induces responses by inhibiting adaptive immune resistance
10.1038/nature13954 · ExternalCitation · doi-reference
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
10.1038/ncomms6241 · ExternalCitation · doi-reference
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma
10.1038/s41379-018-0053-3 · ExternalCitation · doi-reference
The repertoire of mutational signatures in human cancer
10.1038/s41586-020-1943-3 · ExternalCitation · doi-reference
Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas
10.1038/s41598-019-40016-8 · ExternalCitation · doi-reference
Why PD-L1 expression varies between studies of lung cancer: results from a Bayesian meta-analysis
10.1038/s41598-024-80301-9 · ExternalCitation · doi-reference
A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study
10.1093/jjco/hyab202 · ExternalCitation · doi-reference
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma
10.1097/01.jto.0000437008.00554.90 · ExternalCitation · doi-reference
Characteristics and predictive value of PD-L1 status in real-world non-small cell lung cancer patients
10.1097/cji.0000000000000226 · ExternalCitation · doi-reference
Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer
10.1097/jto.0000000000000687 · ExternalCitation · doi-reference
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
10.1097/jto.0b013e318292be18 · ExternalCitation · doi-reference
Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data
10.1097/xeb.0000000000000054 · ExternalCitation · doi-reference
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
10.1111/1759-7714.13684 · ExternalCitation · doi-reference
Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma
10.1111/ajco.13460 · ExternalCitation · doi-reference
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas
10.1111/his.13466 · ExternalCitation · doi-reference
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · ExternalCitation · doi-reference
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
10.1158/1078-0432.ccr-16-2554 · ExternalCitation · doi-reference
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
10.1177/1758835920950207 · ExternalCitation · doi-reference
Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma
10.1177/17588359221133889 · ExternalCitation · doi-reference
Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
10.1177/17588359221136759 · ExternalCitation · doi-reference
Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases
10.1186/1477-7819-11-252 · ExternalCitation · doi-reference
Ringed fluorodeoxyglucose uptake predicted poor prognosis after resection of pulmonary pleomorphic carcinoma
10.1186/s13019-022-01799-6 · ExternalCitation · doi-reference
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis
10.1371/journal.pone.0180346 · ExternalCitation · doi-reference
Genomic variations and immune-related features of TMB, PD-L1 expression and CD8+ T cell infiltration in Chinese pulmonary sarcomatoid carcinoma
10.2147/ijgm.s357659 · ExternalCitation · doi-reference
A high PD-L1 expression in pulmonary pleomorphic carcinoma correlates with parietal-pleural invasion and might predict a poor prognosis
10.2169/internalmedicine.1462-18 · ExternalCitation · doi-reference
Prognostic significance of tumor immunity in surgically resected pulmonary pleomorphic carcinoma
10.21873/anticanres.13948 · ExternalCitation · doi-reference
Immunosuppressive traits of the hybrid epithelial/mesenchymal phenotype
10.3389/fimmu.2021.797261 · ExternalCitation · doi-reference
Immunophenotyping of pulmonary sarcomatoid carcinoma
10.3389/fimmu.2022.976739 · ExternalCitation · doi-reference
Heterogeneous expression of PD-L1, B7x, B7-H3, and HHLA2 in pulmonary sarcomatoid carcinoma and the related regulatory signaling pathways
10.3390/cancers15133372 · ExternalCitation · doi-reference
Integrated clinical, molecular and immunological characterization of pulmonary sarcomatoid carcinomas reveals an immune escape mechanism that may influence therapeutic strategies
10.3390/ijms241310558 · ExternalCitation · doi-reference
Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
10.3904/kjim.2017.245 · ExternalCitation · doi-reference
Genomic landscape of pulmonary sarcomatoid carcinoma
10.4143/crt.2023.764 · ExternalCitation · doi-reference
The prognostic impact of immune checkpoint inhibitors for the treatment of pulmonary sarcomatoid carcinoma: a multicenter retrospective study
10.4149/neo_2022_220617n644 · ExternalCitation · doi-reference
